Evolva

Evolva is a synthetic biology company based in Basel, Switzerland, that develops and commercializes nature-derived specialty ingredients for the global health, wellness, and nutrition markets. The enterprise utilizes advanced biotechnology processes to manufacture commercial-scale compounds, specifically focusing on three primary product categories including nootkatone, resveratrol, and stevia alternatives for various food and beverage applications. Operating as a publicly listed entity since its initial public offering in 2009, the firm significantly expanded its operational capabilities and market reach by acquiring the biotechnology firm Abunda Inc. in 2011. Following a strategic transition from a pharmaceutical-oriented research startup into a commercial product-based business, the organization shifted its corporate focus under executive Simon Waddington toward growing market opportunities, delivering attractive margins, and executing major product launches in 2018. The biotechnology corporation Evolva was officially established in April 2004 by co-founder Neil Goldsmith.